Cervicovaginal microbiota predicts Neisseria gonorrhoeae clinical presentation

Angela Lovett¹, Arlene C. Seña^{2,3}, Andrew N. Macintyre⁴, Gregory D. Sempowski⁴, Joseph A. Duncan^{1,2, 3,5†}, and Andreea Waltmann^{3†}

¹ Department of Pharmacology, University of North Carolina, Chapel Hill, NC, United States

² Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, NC, United States

³ Institute for Global Health & Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

⁴ Department of Medicine and Duke Human Vaccine Institute, Duke University, Durham, NC, United States

⁵ Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

[†] These authors have contributed equally to this work and share senior authorship

Keywords: Neisseria gonorrhoeae, bacterial vaginosis, Lactobacillus, microbiome, symptoms

Abstract

Neisseria gonorrhoeae infection of the female lower genital tract can present with a spectrum of phenotypes ranging from asymptomatic carriage to symptomatic cervical inflammation, or cervicitis. The factors that contribute to the development of asymptomatic or symptomatic infections are largely uncharacterized. We conducted a pilot study to assess differences in the cervicovaginal microbial community of patients presenting with symptomatic vs. asymptomatic N. gonorrhoeae infections to a sexually transmitted infections (STI) clinic. DNA was isolated from cervicovaginal swab specimens from women who tested positive for N. gonorrhoeae infection using a clinical diagnostic nucleic acid amplification test. We performed deep sequencing of 16S ribosomal RNA gene amplicons, followed by microbiome analyses with OIIME, and species-specific real-time PCR to assess the composition of microbial communities cohabitating the lower genital tract with the infecting N. gonorrhoeae. Specimens collected from asymptomatic individuals with N. gonorrhoeae infection and no co-infection with Chlamvdia trachomatis and/or Trichomonas vaginalis carried Lactobacillus-dominant microbial communities more frequently than symptomatic patients without co-infection. When compared to asymptomatic individuals, symptomatic women had microbial communities characterized by more diverse and heterogenous bacterial taxa, typically associated with bacterial vaginosis (BV) (Prevotella, Sneathia, Mycoplasma hominis and Bacterial Vaginosis-Associated Bacterium-1 (BVAB1)/"Candidatus Lachnocurva vaginae). Both symptomatic and asymptomatic N. gonorrhoeae patients with additional STI co-infection displayed a BV-like microbial community. We used a murine model of N. gonorrhoeae infection in mice pre-colonized with Lactobacillus crispatus to test whether pre-existing L. crispatus was protective from N. gonorrhoeae colonization or whether N. gonorrhoeae infection could drive the loss of L. crispatus during infection. Vaginal infection with either N. gonorrhoeae strain 1291 or an isogenic mutant known to exhibit lower inflammatory had no impact on Lactobacillus burden recovered from the mice. These data taken together suggest that Lactobacillusdominant vaginal microbial community may protect individuals from developing symptoms during lower genital tract infection with N. gonorrhoeae.

1 Introduction

2 *Neisseria gonorrhoeae* is a sexually transmitted bacterial pathogen responsible for 90 million infections 3 globally each year [1]. N. gonorrhoeae is a strictly human pathogen and infections are typically localized 4 to the lower genital tract. Although acute symptomatic infection is often recognized and treated with 5 6 7 antibiotic therapy, a surprisingly large proportion of N. gonorrhoeae infections are asymptomatic [2-4]. Upwards of 50% of lower genital tract infections in females are asymptomatic [5, 6]. While the prevailing dogma is that male urethral infections are symptomatic, compelling reports have documented that 8 asymptomatic genital gonorrhea is prevalent in both biological sexes and across a wide range of settings 9 [2, 7-11]. Asymptomatic infection is not without consequence. Untreated asymptomatic infections can 10 ascend to the upper genital tract leading to health complications including pelvic inflammatory disease and 11 infertility in women [12-14]. Asymptomatic genital N. gonorrhoeae poses a risk of onward transmission to 12 sex partners and ascending infection. Mathematical models of gonorrhea transmission have confirmed 13 unequivocally the significant contribution of subclinical infections in maintaining community transmission 14 [15]. The determinants and mechanisms that underlie asymptomatic and symptomatic gonorrhea infection 15 are unknown. This knowledge gap greatly hinders efforts to develop new strategies for gonorrhea control.

16

17 Symptomatic N. gonorrhoeae infection most commonly leads to localized host inflammation at the site of 18 infection, urethritis in males, and cervicitis in females. N. gonorrhoeae itself is resistant to many host 19 antimicrobial responses which may contribute to its ability to cause infection under these conditions of 20 localized inflammation. During an infection, N. gonorrhoeae must compete with the natural microbial 21 community at the mucosal surface to establish infection [16]. Cervicovaginal microbial communities play 22 an important role in sexual and reproductive outcomes, including protection from pathogens, as the 23 composition of the cervicovaginal microbiota has been shown to modify susceptibility to several sexually-24 transmitted pathogens (STI) [17-23]. For example, human vaginal microbiota dominated by Lactobacillus 25 crispatus is associated with reduced risk of acquisition of STI, like HIV [24-27]. In addition, women with 26 clinically apparent bacterial vaginosis (BV), a clinical condition characterized by depleted levels of 27 of Lactobacillus species and an increased abundance of diverse groups of facultative anaerobes, have an 28 increased risk of acquiring and transmitting STI, including N. gonorrhoeae [24, 28-30] and at an increased 29 risk of adverse reproductive and obstetric outcomes [31-33], irrespective of whether the BV is symptomatic 30 or not [17, 33, 34]. These factors indicate a mechanistic contribution of L. crispatus to protection from STI, 31 presumably through the production of lactic acid and thus the maintenance of a low-pH vaginal 32 microenvironment [35]. The reasons why the microbiota of some women is dominated by Lactobacillus 33 species, whereas that of others becomes dominated by anaerobes are not completely understood.

- 34 35 Molecular definitions of the cervicovaginal microbiota of reproductive age women, with respect to 36 microbial composition and diversity, are now standard [21, 27, 36]. Using 16S rRNA sequencing or 37 metagenomics, distinct cervicovaginal microbial community types (CTs) have been classified [21, 27, 36]. 38 The "optimal types" CT1 and CT2 are dominated by L. crispatus and L. gasseri, respectively. The other 39 two Lactobacillus-dominant molecular community types are L. iners (CT3) and L. jensenii (CT5). Notably, 40 not all Lactobacillus-dominant types are equal in their protective effect against STI, as L. iners-dominated 41 vaginal microbiotas may actually place patients at higher risk of STI infection, like chlamydia or HIV, when 42 compared to L. crispatus-dominant microbiotas [25-27]. Finally, CT4 communities are characterized by a 43 diverse and heterogenous group of anaerobes (e.g. Atopobium, Prevotella, Dialister, Gardnerella, 44 Megasphaera, Peptoniphilus, Sneathia, Eggerthella, Aerococcus, Finegoldia, and Mobiluncus [36]) and 45 this vaginal environment is a significant risk factor for having clinically-diagnosed bacterial vaginosis (BV)
- 46 [37-39] and is termed molecular-BV [34].
- 47

48 Studies examining the impact of vaginal microbiomes on inflammatory states found that women with

- 49 clinical-BV or molecular BV (i.e. CT4 microbial communities) had higher cervicovaginal levels of pro-
- 50 inflammatory cytokines (IL-1 α , IL-1 β , IL-6, IL-12 and IL-8) than BV-negative or *Lactobacillus*-dominant
- 51 women, respectively [22, 27, 40]. Notably, the more the vaginal microbiota shifts away from a state

52 dominated by *L. crispatus* towards dysbiosis (i.e. towards CT3 and CT4 types) the more marked the 53 inflammation [21, 41, 42], independently of concurrent STIs, including gonorrhea [21]. This indicates that 54 the variations in vaginal microbial diversity that are common in women with BV could influence 55 inflammatory responses that characterize symptomatic *N. gonorrhoeae* infection.

56

57 We sought to understand whether differences in microbial composition of the genital tract were associated 58 with symptomatic or asymptomatic presentation of N. gonorrhoeae infection, by utilizing 16S ribosomal 59 RNA (rRNA) amplicon deep sequencing of clinician-collected cervicovaginal specimens from females 60 diagnosed with gonorrhea. Because the causal relationship between gonorrhea infection, development of 61 symptoms, and presence of L. crispatus remains an open question in the field, we conducted experiments 62 with controlled infection models of N. gonorrhoeae in mice pre-colonized to test whether N. gonorrhoeae 63 infection could drive the loss of pre-existing L. crispatus during infection or if L. crispatus differentially 64 protected against infection with N. gonorrhoeae strains with different inflammatory potential. 65

66 <u>Methods</u>

67

77

68 Study Population and Sample Collection

69 Specimens used in this study were remnant specimens collected from female patients that attended a public 70 sexually transmitted infection (STI) clinic located in Durham, North Carolina in 2011 and tested positive 71 for Neisseria gonorrhoeae using the clinical diagnostic assay Aptima Combo 2® assay (for CT/NG) by 72 Hologic. Clinician-collected cervicovaginal swabs used for diagnosis were collected as per routine care 73 prior to any treatment. The age, race, reported symptoms, and diagnosis for each study subject were linked 74 to each specimen by a study clinician when a positive specimen was identified. The de-identified remnant 75 cervical swab samples were stored in Aptima buffer in their respective transport tubes at -80°C until DNA 76 extraction was performed.

78 **DNA Extraction**

79 200 µL of Aptima buffer from each sample were transferred to sterile 2 mL tubes containing 200 mg of 80 ≤100 µm glass beads (Sigma), 0.3 mL of 20mg/mL lysozyme solution (Thermo Fisher) and 0.3 mlL of 81 Qiagen ATL buffer. Bead-beating was then carried out for 10 minutes in a Qiagen TissueLyser II at 30Hz 82 to ensure optimal DNA yield from Gram-positive bacteria. Subsequently, samples were incubated at 37°C 83 for 30 minutes. After a brief centrifugation, supernatants were aspirated and transferred to a new sterile 84 tube with Qiagen AL buffer containing Proteinase K (600 IU/µL). Samples were then incubated at 70°C 85 for 10 minutes. DNA was purified using a standard on-column purification method using Zymo-spin mini 86 columns and Qiagen buffers AW1 and AW2 as washing agents. DNA was eluted in 100 µL of 10 mM Tris 87 (pH 8.0).

88

89 16S Ribosomal RNA Sequencing

90 For amplicon library preparation we used fusion primers composed of Ion Torrent adapter 5'-91 -3' for the and 5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG forward primer 92 CCTCTCTATGGGCAGTCGGTGAT -3' for the reverse primer, and universal bacterial primer 8F 5'-93 AGAGTTTGATCCTGGCTCAG-3' and 338R 5'-GCTGCCTCCCGTAGGAGT-3'. The forward primer also 94 included a 10 bp IonXpress[™] barcode, unique to each sample. Each bacterial DNA sample was run in 95 duplicate in a 25 µL PCR reaction containing: 4 µL of 5x MyTag Reaction Buffer (Bioline); 0.6 µL each 96 of 15 µM Forward Primer and 15 µM Reverse Primer (Integrated DNA Technologies); 0.5 µL MyTaq HS 97 DNA Polymerase (Bioline); 100 ng template DNA; water to 25 µL. Samples were denatured at 94°C for 5 98 minutes, followed by 35 cycles of 94°C for 45 seconds, 55°C for 45 seconds and 72°C for 90, followed by 99 an extension at 72°C for 10 minutes and a 4°C hold. Each sample was visualized on a 2 % agarose gel. 100 Bands were excised and duplicate bands were combined into one tube. Gel purification was performed 101 using the Qiagen Gel Extraction Kit (Qiagen) according to the manufacturer's protocol. Samples were 102 quantified using an Agilent 2100 Bioanalyzer (Agilent). Quantification information was used to create a

103 library by combining equimolar concentrations of each sample. The prepared library was sequenced on the

- 104 Ion Torrent PGM Instrument (Life Technologies) according to the manufacturer's protocol at UNC-CH 105 High Throughput Sequencing Facility.
- 106

107 **Sequence Data Analysis**

108 Sequencing output was demultiplexed and the resulting paired-end reads were joined using the QIIME 1.9.0 109 [43] by invocation of fastg-join with the default parameters. Index and linker primer sequences were 110 trimmed, and the reads were subsequently filtered for quality using a sliding window of 50 bases, moving 111 by 5 bases, requiring an average quality score of 20 or above. Quality control of both raw and processed 112 sequencing reads was verified by FastQC [44]. Sequences were clustered into operational taxonomic units 113 (OTU) based on the *de novo* OTU picking algorithm using the QIIME implementation of UCLUST [45] at 114 a similarity threshold of 97%. OTUs identified as chimeric by vsearch [46] of the ChimeraSlayer "gold" 115 reference database [47] and those composed of a single read (singletons) were eliminated. The remaining 116 OTUs were assigned taxonomic identifiers with respect to the Greengenes database [48], their sequences 117 were aligned using template alignment through PyNAST [49], and a phylogenetic tree was built with 118 FastTree 2.1.3 [50]. If after the Greengenes taxonomic assignment a taxon of interest was ambiguous at the 119 genus level or when putative species taxonomy was sought, we consulted the 16S sequences in the National 120 Center for Biotechnology Information (NCBI) Genbank repository with the Basic Local Alignment Search 121 Tool (BLAST) [51] and/or with the multiple sequence comparison by log-expectation method (MUSCLE)

- 122 implemented in Geneious using reference genomes.
- 123

124 **Microbiome Analyses**

- 125 Alpha diversity was measured by three different metrics (Chao1; and observed species; phylogenetic
- 126 diversity, PD) using QIIME. Beta diversity estimates were calculated within QIIME using weighted and
- 127 unweighted Unifrac distances [52] between samples. Results were summarized and visualized through
- 128 principal coordinate analysis (PCoA) in QIIME. Cervicovaginal community types (CTs) were assigned
- 129 using established definitions [21, 27, 36] based on diversity and relative abundance of bacterial taxa.
- 130 These definitions classify samples with relative majority abundance assigned to *Lactobacillus crispatus*,
- 131 L. gasseri, L. iners or L. jensenii as CT1, CT2, CT3, CT5, respectively. According to the same
- 132 definitions, low Lactobacillus communities comprising a diverse and heterogenous group of anaerobes
- 133 (e.g. Atopobium, Prevotella, Dialister, Gardnerella, Megasphaera, Peptoniphilus, Sneathia, Eggerthella,
- 134 Aerococcus, Finegoldia, and Mobiluncus are classified as CT4 or "molecular bacterial vaginosis" [34].
- 135

136 **Microbial DNA qPCR Array**

137 The Vaginal Flora Microbial DNA qPCR Array (Cat. no. 330261 BAID-1902Y, Qiagen) was used for 138 vaginal microbiome profiling. Each specimen was processed and run on the 96 well array plate format. The 139 array contained assays for the detection of 90 microbial species, 2 Pan bacteria controls (Pan Bacteria 1, 140 Pan Bacteria 3), 1 Pan Fungi control (Pan Aspergillus/Candida), 2 host controls (Hs/Mm.GAPDH 141 Hs/Mm.HBB1) and a positive PCR control (PPC). 500 ng of genomic DNA was mixed with 1,275 µL 142 microbial qPCR Mastermix and water as needed to bring the total volume to 2,550 µL, using the 143 manufacturer's instructions. Individual reaction mix aliquots of 25 µL were added to each well of the plate, 144 the array plate was tightly sealed, centrifuged at 1000 rpm for 1 min and loaded onto the Real-Time PCR 145 machine. PCR was performed with an initial PCR activation step at 95°C for 10 minutes, followed by 2-146 step cycling of denaturation for 15 seconds at 95°C, with annealing and extension for 2 minutes at 60 °C 147 for 40 cycles. The CT values for each well were imported into the Microbial DNA qPCR Array Excel 148 template (Qiagen) for analysis. The ΔCT between the patient sample DNA and no DNA template negative 149 control was calculated for each set of species-specific primer sets, following manufacturer's instructions

150 for analysis. A species was reported as "present, +" if ΔCT was >3, an 8-fold increase in signal over 151 background.

152 **Murine Infection Models**

153 The protocol for murine vaginal N. gonorrhoeae infection was adapted from a model previously described 154 by Jerse et al. [53]. In brief, 4 to 6 week-old female BALB/c mice were synced in the proestrous stage of 155 their estrous cycle by administering β -estradiol on days -2, 0 and 2 of infection. Mice were also given daily 156 intraperitoneal injections of streptomycin sulfate to promote infection through reduction of commensal 157 organisms. L. crispatus was acquired from the American Tissue Culture Collection (ATCC, 33820TM) and 158 was used to establish the pre-colonized Lactobacillus vaginal model. Mouse infection with N. gonorrhoeae 159 strains 1291 (wild-type) and 1291 $\Delta msbB$ (mutant) have been previously described [54]. Prior to infection, 160 bacterial strains were grown overnight (18 hour) on De Man, Rogosa and Sharpe (MRS) agar for L. 161 crispatus or Gonococcal Base (GCB) agar for N. gonorrhoeae at 37°C in 5% CO₂, harvested and transferred 162 into PBS for inoculation. Bacterial suspensions were quantified by measuring the optical density at 600 nm 163 (OD_{600}) . Mice were pre-colonized with L. crispatus by vaginal inoculation on day -1 with an estimated 10^8 164 CFUs of L. crispatus prepared in PBS. Mice were subsequently infected with N. gonorrhoeae (1291 or 165 $1291-\Delta msbB$) by vaginal inoculation with an estimated 10^6 CFUs of the indicated N. gonorrhoeae strain in 166 PBS on day 0. Vaginal swabs were collected daily from each mouse for 10 days following inoculation with 167 N. gonorrhoeae. The quantity of L. crispatus was determined by plating of serial dilutions of the vaginal 168 swabs on MRS agar. The quantity N. gonorrhoeae was determined by plating of serial dilutions of the 169 vaginal swabs on (GCB) agar supplemented with vancomycin, colistin, nystatin, trimethoprim (VCNT).

170

171 **Statistical Analyses**

172 Statistical analyses were performed in PRISM 9 or STATA 16. Differences in donor characteristics and 173 between sample groups were investigated using the Fisher's exact test. We compared α -diversity between 174 sample groups with non-parametric two-sample t-tests using 1000 Monte Carlo permutations to calculate 175 the p-values. To test whether sample groups were statistically different we used non-parametric ANOSIM 176 (ANalysis Of Similarities) tests and non-parametric two-sample *t*-tests with 1000 Monte Carlo 177 permutations to derive p-values implemented in QIIME. Kaplan-Meier curves were used to estimate 178 clearance of N. gonorrhoeae and time to clearance (in days) in the mouse model of infection. For 179 comparisons between multiple groups one way ANOVA was used, correcting for multiple comparisons 180 with Tukey post hoc tests. 181

182 Results

183

184 Cohort characteristics of N. gonorrhoeae infected women

185 In this pilot study, we used remnant nucleic acid material from cervical swabs collected from a convenience 186 sample of 19 women deemed to be N. gonorrhoeae-positive by Aptima clinical diagnostic testing. Of these, 187 ten individuals reported symptoms to the provider (defined as symptomatic) and nine did not (defined as 188 asymptomatic) (Table 1). The reported symptoms at the time of cervical swab sampling included vaginal 189 discharge (9/10, 90.0%), genital irritation (1/10, 10.0%), and dysuria (2/10, 20%). There was a trend for 190 younger women to report symptoms (p=0.090). Of the 19 specimens, 17 (89.5%) were collected from 191 women who identified as having African American race. Among the African American women, the 192 proportion of symptomatic and asymptomatic individuals was comparable (p=0.211). The presence or 193 absence of C. trachomatis, another STI pathogen, was assessed by NAAT testing in conjunction with 194 clinical N. gonorrhoeae testing, and no difference in C. trachomatis prevalence was observed between 195 asymptomatic and symptomatic presentation (p=0.590).

196

197 Since other STI pathogens could also be responsible for causing lower genital tract symptoms (e.g. 198 Trichomonas vaginalis or Mycoplasma genitalium), we used a commercial microbial qPCR array to test for

- 199
- the presence of other STI pathogens (Table 2). Specimens from two women did not provide evaluable
- 200 results due to insufficiently recovered DNA material. Among the 17 specimens that gave analyzable results
- 201 on this array, 6 of 7 (85.7%) asymptomatic specimens and 8 of 10 (80.0%) symptomatic specimens had
- 202 detectable Neisseria species DNA (Table 2). Because these specimens all tested positive for N. gonorrhoeae

203 using the APTIMA Combo 2, these results indicate that the sensitivity of the microbial qPCR array may be 204 lower for detecting N. gonorrhoeae in this specimen type than the APTIMA Combo 2. C. trachomatis was 205 detected in 3 of 3 specimens that were positive by APTIMA Combo 2 test and had evaluable qPCR results 206 in the qPCR array (Table 2). T. vaginalis was detected in 4 of 10 (40.0%) evaluable symptomatic individuals 207 and 2 of 7 (28.6%) asymptomatic individuals (Table 2). M. genitalium was not detected by qPCR array in 208 any of the specimens (Table 2). When accounting for both clinical C. trachomatis testing by APTIMA 209 Combo 2 and real-time PCR array results, the proportion of STI co-infection with C. trachomatis or T. 210 vaginalis was not significantly different between symptomatic (5/10, 50.0%) and asymptomatic (5/9, 211 55.6%) individuals (p=0.625). Because co-infection with other STI pathogens was not associated with 212 symptomatic presentation we next sought to assess whether the non-STI vaginal microbial community was 213 associated with the presence or absence of symptoms.

214

215 *Neisseria spp.* abundance represents a small proportion of bacterial communities in both 216 symptomatic and asymptomatic patients.

- 217 The genital microbial community of the 19 study participants was characterized with 16S amplicon deep
- 218 sequencing. A total 157,006 paired-end reads were obtained. After demultiplexing and elimination of
- 219 low-quality reads, 100,216 reads were retained for downstream analyses of alpha diversity and beta
- diversity (mean number of reads per sample = 5,274; range = 2,470-9,528 reads). Paired reads were
- deposited in the Sequence Read Archive (SRA) under the accession PRJNA768436. The individual
- 222 microbial communities of *N. gonorrhoeae* infected patients were compared to those who presented with
- and without symptoms. Because other STI pathogens might be associated with different microbial community profiles, we also compared specimens from individuals without co-infecting *C. trachomatis*
- or *T. vaginalis* (by clinical test and/or real-time PCR) separately from those with co-infection. We first
- examined whether the relative abundance of *Neisseria ssp.* assigned reads was associated with
- symptomatic presentation. *Neisseria*-assigned reads made up only 0.24% of all reads in the dataset and
- 228 were a minor component of the bacterial community in each individual (Figure 1). In this limited set of
- specimens, the point estimate of the relative of abundance of reads from Neisseria spp. was highest in
- 230 symptomatic individuals without *C. trachomatis* or *T. vaginalis* co-infection, though no significant
- 231 difference in relative abundance between any group was observed (Figure 1).
- 232

Microbial community diversity is different between symptomatic and asymptomatic *N. gonorrhoeae* infection

- The overall alpha diversity did not differ when observed taxa, Chao1 and phylogenetic diversity were compared between individuals with symptomatic and asymptomatic *N. gonorrhoeae* infection (Figure 2A, Figure S1 A-C) and between individuals with and without other STI (Figure 2B, Figure S1 D-E). However, the number of dominant taxa comprising the majority of the microbial community (i.e., 90% of all detected taxa) was significantly lower in individuals with asymptomatic *N. gonorrhoeae* infection without STI coinfection *vs.* both individuals with symptomatic *N. gonorrhoeae* and with STI co-infection (Figure 2C).
- Differences between symptomatic and asymptomatic patients, but not between patients with and without *C. trachomatis* and/or *T. vaginalis* co-infection, were reflected in beta diversity analyses, with statistically
 significant ANOSIM tests and clear separation on PCoA plots by two different methods: weighted Unifrac
- ANOSIM R = 0.20, p-value = 0.032, Figure 3A) and unweighted Unifrac ANOSIM R = 0.24 p-value =
- 246 0.011, Figure 3B).
- 247

Asymptomatic patients without an STI co-infection are more frequently characterized by low diversity, *Lactobacillus*-dominant genital communities

- 250 The relative abundance of *Lactobacillus spp.* assigned reads differed by patient group. The distribution of
- 251 Lactobacillus spp. relative abundances was: 92.2% among asymptomatic individuals with no co-infection,
- 35.3% among asymptomatic individuals with co-infection, 21.6% among symptomatic individuals with no
- co-infection, and 11.5% among symptomatic individuals with co-infection (Figure 4A). This was evident

254 when inspecting the individual taxa plots (Figure 4B), as the four asymptomatic patients with only N. 255 gonorrhoeae infection and no detected co-infection were dominated by Lactobacillus taxa, whereas 256 Lactobacillus-predominance was observed less frequently in specimens from women with symptomatic N. 257 gonorrhoeae infection regardless of the presence of additional STI (2/10, 20.0% symptomatics vs. 6/9, 258 66.7% asymptomatics, p=0.040, Figure 4A). Differences in within-patient relative abundance of 259 Lactobacillus spp. in symptomatics with gonorrhea only vs. asymptomatics with gonorrhea were 260 statistically significant (p=0.019, Figure 5A). Similarly, the within-patient relative abundance of 261 Lactobacillus spp. in symptomatics with gonorrhea only vs. that of symptomatic with co-infections also 262 varied significantly (p=0.007, Figure 5A).

263

Using BLAST and MUltiple Sequence Comparison by Log Expectation (MUSCLE) [55], we investigated the 16S sequences of each taxa that was assigned *Lactobacillus* taxonomy and identified *L. iners* as the likeliest species (Supplementary Table 1). This led us to define *Lactobacillus*-dominant samples (n=8) as community-type 3 (CT3), using standard definitions of vaginal microbial structure [21, 27, 36] (Figure 4B).

268

The presence of specific *Lactobacillus* species was further assessed by presence/absence real-time PCR (Figure 5B). The *Lactobacillus* species most commonly detected among all women were *L. iners*, *L. crispatus*, *L. jensenii*, and *L. gasseri* (Figure 5B). In line with our microbiome analyses and BLAST homology searches, all asymptomatic women were positive for *L. iners*, and in 85% and 75% of symptomatic women with and without co-infection, respectively. Although *L. crispatus* was not the predominant *Lactobacillus* species in any of the specimens using 16S sequencing, *L. crispatus* was detected by real-time PCR only in *N. gonorrhoeae*-infected individuals with asymptomatic presentation (Figure 5B).

276

Symptomatic *N. gonorrhoeae* and STI co-infection are associated with a diverse cervicovaginal microbial community composed of bacterial vaginosis-associated bacteria

279 Having established that 8 of 19 samples (42.1%) were L. iners-dominated (CT3) and more commonly 280 associated with asymptomatic N. gonorrhoeae infection, we investigated in more detail the remaining 11 281 samples, which were dominated by a diverse group of non-lactobacilli (Prevotella, a Lachnospiraceae 282 genus, Sneathia, or Mycoplasma). We used BLAST and MUSCLE alignments to further characterize the 283 composition of the non-Lactobacillus communities dominated by Lachnospiraceae and Mycoplasma. By 284 applying BLAST on representative reads assigned to each genus of interest, we found that the likeliest 285 species for Lachnospiraceae and Mycoplasma OTUs were Bacterial Vaginosis-Associated Bacterium-1 286 (BVAB1)/"Candidatus Lachnocurva vaginae" and M. hominis, respectively (Supplementary Table 1). 287 Samples dominated by Prevotella (n=6), Sneathia (n=1), BVAB1 (n=3), and M. hominis (n=1) were 288 classified as CT4/molecular BV. The *Mycoplasma*-dominant sample was included in the CT4 and 289 molecular BV classifications. The CT4/molecular BV samples were more frequently found in symptomatic 290 patients (8/10, 80% of symptomatics vs. 3/9, 33.3% of asymptomatics, p=0.040) (Figure 4B). Among STI 291 co-infected individuals, 7/10 (70.0%) carried CT4 microbial communities compared to patients without co-292 infections (4/9, 44.4%), though this difference did not attain statistical significance (p=0.255).

293

294 The prevalence of common bacterial vaginosis-associated bacteria was also assessed by commercially-295 available microbial DNA real-time PCR assay (Figure 6). Of the BV-associated species included in the 296 panel, Gardnerella vaginalis, was present in all samples. Other species commonly associated with BV, like 297 Atopobium vaginae, certain Prevotella spp., and Sneathia sanguinegens were also highly prevalent among 298 this cohort of women, regardless of symptoms or STI co-infection status. Asymptomatic women infected 299 only with N. gonorrhoeae (n=4) carried the following species less frequently than symptomatic women 300 infected only with N. gonorrhoeae (n=5): M. hominis (25% vs. 80%), Prevotella buccalis (25% vs. 80%), 301 and Ureaplasma urealyticum (0% vs. 100%). Similarly, asymptomatic females without co-infections also 302 carried BV-associated bacteria less frequently when compared to those with symptoms or STI co-infections 303 (Figure 6).

304

305

306 A murine model does not support direct impact of N. gonorrhoeae on L. crispatus vaginal colonization 307 Though the microbial community in N. gonorrhoeae infected women was different between those with and 308 without symptoms, it is not clear whether symptomatic infection drives reduced Lactobacillus abundance 309 or whether pre-existing low Lactobacillus abundance or presence of BV-associated microbial communities 310 leads to symptomatic infection. To test whether N. gonorrhoeae infection could affect the abundance of 311 Lactobacillus present in the vagina, mice pre-colonized with L. crispatus, which we had found was present 312 only in asymptomatic N. gonorrhoeae infected individuals, were infected with either wild type N. 313 gonorrhoeae strain 1291 or an isogenic mutant strain lacking the msbB locus (1291 Δ msbB). Our group has 314 previously shown this mutant strain induces less localized inflammation, a state that would be consistent 315 with reduced or absent symptoms in human infection. Lactobacillus colonization was maintained 316 throughout the infection in all mice, regardless of N. gonorrhoeae infection status. No substantial difference 317 was observed in Lactobacillus burden between uninfected control mice and mice infected with either strain 318 of N. gonorrhoeae (Figure 6A). To test whether the presence of L. crispatus differentially impacted the 319 ability of "symptomatic" or "asymptomatic" infection inducing N. gonorrhoege strains to establish and/or 320 maintain an infection in mice, we quantified the percentage of mice infected with wild type or the $\Delta msbB$ 321 strain over the course of the 10-day infection period. The presence of L. crispatus did not have a significant effect on the ability of the mice to clear wild-type N. gonorrhoeae infection (Figure 6B) or type N. 322 323 gonorrhoeae infection with the mutant strain (Figure 6C). These findings are consistent with previous 324 studies in mice using N. gonorrhoeae and Lactobacillus inoculation conducted on the same day [56]. 325 Although there are caveats between mouse model and human data, our findings suggest that the presence 326 of L. crispatus is not impacted by N. gonorrhoeae infection and that prior colonization with L. crispatus 327 does not have a differential effect on N. gonorrhoeae infection regardless of the capacity of the N. 328 gonorrhoeae to induce localized inflammation in the female mouse model of lower genital tract infection. 329

330 Discussion

331 A large body of evidence links vaginal dysbiosis, such as clinical bacterial vaginosis (BV) to the risk of 332 acquisition of several sexually-transmitted infections (STIs), including gonorrhea [17, 25, 30, 33, 57]. 333 Despite the clear association between BV and STI acquisition risk, treatment of asymptomatic BV has not 334 been found to reduce the incidence of N. gonorrhoeae or C. trachomatis infection incidence, raising the 335 question whether a suboptimal vaginal environment is a modifiable biological cause of gonorrhea risk [58]. 336 However, Lactobacillus-based live probiotic therapy of vaginal dysbiosis has been recently shown to reduce 337 not only BV [16, 59], but also bacterial STI incidence [60]. To the best of our knowledge, this report is the 338 first to examine the association between the cervicovaginal microbiota composition and symptomatic N. 339 gonorrhoeae infections in women. Using 16S ribosomal RNA gene deep sequencing approaches on patient 340 samples confirmed to be infected with *Neisseria gonorrhoeae* by APTIMA clinical testing, we show that 341 the cervicovaginal microbiome is predictive of gonorrhea clinical presentation in women attending an STI 342 clinic in the United States. These findings were confirmed by real-time polymerase chain reaction assays 343 specific for several Lactobacillus species and BV-associated bacteria deployed in parallel on the same 344 clinical samples.

345

346 Specimens collected from asymptomatic individuals with N. gonorrhoeae infection and no co-infection 347 with Chlamvdia trachomatis and/or Trichomonas vaginalis carried Lactobacillus-dominant microbial

348 communities more frequently than symptomatic patients without co-infection. Notably, this Lactobacillus

349 dominance was due to *L. iners* and these microbiotas were classified as community type 3 (CT3),

350 according to established definitions in the field [21, 27, 36]. Previous studies have established that L. 351 iners-dominated vaginal microbiotas compared to L. crispatus-dominated vaginal microbiotas may place 352 patients more at risk of STI infection, like chlamydia or HIV [25-27]. Interestingly, none of the females

353 in our study had cervicovaginal microbiomes dominated by L. crispatus, which may be consistent with a 354 protective effect by L. crispatus on STI infection risk. This is supported by in vitro studies with

355 clinically-isolated and lab strains of L. crispatus have been shown to inhibit the growth of N. gonorrhoeae 356 in vitro [64], possibly through the effects of lactic acid acidification of the growth environment [65]. 357 While L. crispatus produces both isomers of lactic acid, L. iners and human cells only make l(+) lactic 358 acid [66, 67]. Accumulating evidence also suggests that d(-) lactic acid may impart greater protection 359 against STI pathogens than l(+) lactic acid potentially via effects on human host cells rather than 360 pathogen cells [68, 69]. In humans, L. crispatus-dominant vaginal microbiota is associated with reduced

361 risk of acquisition of other STI, like HIV [24-27].

362 363

364 N. gonorrhoeae-infected patients who reported symptoms were found to have genital microbiomes 365 composed of a mixture of various bacterial anaerobes, such as Prevotella, Sneathia, Mycoplasma hominis 366 and Bacterial Vaginosis-Associated Bacterium-1 (BVAB1)/"Candidatus Lachnocurva vaginae" [70]. 367 These women with genital microbiomes composed of anaerobes were deemed to have molecular bacterial 368 vaginosis (BV), as defined by established classifications in the field based on diversity and relative 369 abundance of bacterial taxa [21, 27, 36]. This included the Mycoplasma-dominant sample because of three 370 main reasons that definitions of molecular BV take into account: like Prevotella and Sneathia, it can 371 overgrow in cases of BV [71, 72], its prevalence in BV patients is three times higher compared to healthy 372 women [73] and it is associated with severe genital mucosal inflammation [74].

373

374 A possible explanation for the association of symptoms in N. gonorrhoeae infection and BV-associated 375 microbial communities relates to the known increase of inflammation and inflammatory mediators in 376 women with BV. Several studies have shown that females with clinical BV or low Lactobacillus abundance

377 and high diversity of anaerobes also harbor higher concentrations of pro-inflammatory cytokines in their

- 378 genital tract [21] and higher levels of the pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-12 and IL-8)
- 379 when compared to BV negative women [75]. Further, symptoms of abnormal vaginal discharge were also
- 380 found to associate with elevated levels of IL-18, IP-10, IL-8, and GCSF, linking inflammatory cytokines to

vaginal symptoms, particularly vaginal discharge[75]. Notably, the more the vaginal microbiota shifts towards dysbiosis, the more marked the inflammation [21, 41, 42], independently of concurrent STIs,

- 383 including HIV and gonorrhea [21].
- 384

385 We recognize that our study with clinical specimens had limitations. Because of the nature of the study 386 design, we had no information on whether our symptomatic subjects also had clinically defined BV. 387 However, the association between BV associated microbes and cervicovaginal community type suggests 388 that further studies of the association of BV with symptomatic N. gonorrhoeae infection are needed. We 389 lacked specimens from N. gonorrhoeae-negative women and the majority of our study participants 390 identified as African American. Previous BV prevalence studies reported that compared to Caucasian 391 women, low-Lactobacillus vaginal microbiotas are more common in African American and Latin women 392 [36, 61, 62] and that up to 50% of African American women may harbor vaginal microbiotas deplete in 393 Lactobacillus species [63]. Future studies on how race, the vaginal microbiota and N. gonorrhoeae risk 394 intersect are needed.

395

396 Our study using human clinical specimens showed that symptomatic vs. asymptomatic gonorrhea 397 presentation is correlated with having molecular BV, leading to two possible explanations. First, that the 398 molecular BV community type compared to the L. iners dominated community type may have predisposed 399 to the development of gonococcal-associated symptoms. Second, that the BV state developed after or was 400 even caused by the establishment of N. gonorrhoeae infection due to the promotion of the growth of BV-401 associated bacteria or a loss of Lactobacillus species. Given the compelling evidence supporting a 402 protective effect of L. crispatus on STI infection risk, we tested whether the level of L. crispatus 403 colonization was impacted by either wild type or hypo-inflammatory N. gonorrhoeae infection in a murine 404 model. However, no change in L. crispatus colonization was observed in mice infected with either N. 405 gonorrhoeae strain. We also utilized this murine model to examine whether L. crispatus, which was only 406 found in asymptomatic N. gonorrhoeae-infected humans, might reduce bacterial burden of wild-type N. 407 gonorrhoeae or support the expansion of hypo-inflammatory N. gonorrhoeae that could theoretically be 408 associated with asymptomatic infections. We found no impact of L. crispatus pre-colonization on N. 409 gonorrhoeae burden from either strain. Because the murine model of N. gonorrhoeae infection may not 410 fully reflect pathogenesis of N. gonorrhoeae infection in humans, future studies examining the microbiome 411 longitudinally during infection are needed to provide insight into whether N. gonorrhoeae can influence 412 the genital microbial composition of the host or whether pre-existing microbial composition can influence

- 413 disease presentation.
- 414

415 Overall, our findings suggest that the cervicovaginal microbiota is a determinant, or at least a contributor, 416 to gonorrhea clinical presentation in women. Further studies defining the relationship between genital tract

- 416 to gonorrhea clinical presentation in women. Further studies defining the relationship between genital tract 417 microbiomes and the and pro-inflammatory immune responses in symptomatic presentation of *N*.
- 418 gonorrhoeae infection are needed to elucidate whether *Lactobacilli* or BV-defining microbial communities
- 419 serve as a biomarker for symptoms in *N. gonorrhoeae* infections or directly impact symptoms.
- 420

421 Acknowledgments

- 422 We extend our sincere thanks to Adriane Osborne, WNP, and to the STI clinic staff and participants at the
- 423 Durham County Public Health Department for making this study possible. We thank UNC Microbiome
- 424 Core, and in particular Dr. M. Andrea Azcarate-Peril and Dr. Jeff Roach, for the excellent execution of 425 the library preparation and sequencing, and subsequent analysis support.
- 426

427 Ethics Statement

- 428 The studies involving human derived specimens were reviewed and approved by the University of North
- 429 Carolina Institutional Review board (Studies 11-0047 and 15-2531). The research was found to meet the
- 430 criteria for a waiver of informed consent for research [45 CFR 46.116(d)] and waiver of HIPAA
- 431 authorization [45 CFR 164.512(i)(2)(ii)] as the study entailed research on existing specimens, posing

- 432 minimal risk to participant, the waiver did not adversely affect the rights or welfare of the participants and 433 consent/assent would have been impracticable given the loss to follow up. The mouse N.
- 434 *gonorrhoeae* infection studies were reviewed and approved by the University of North Carolina at Chapel
- 435 Hill Institutional Animal Care and Use Committee (IACUC ID numbers 15-217 and 18.150).
- 436
- 437

438 <u>Funding</u>

439 The project described was supported by the National Center for Advancing Translational Sciences, National 440 Institutes of Health, through Grant Award Number TL1TR002491 supporting Andreea Waltmann and 441 through an NC TraCS Pilot Grant supported by Grant Award Number UL1TR002489 awarded to Joseph 442 Duncan. Additionally, the project was supported by the National Institute of Allergy and Infectious 443 Diseases, National Institutes of Health, through the UNC program for Training in Sexually Transmitted 444 Infections and HIV (T32AI007001) supporting Angela Lovett and by Grant Award Numbers U19AI113170 445 and AI144180 awarded to Joseph Duncan, Andrew Macintyre and Gregory Sempowski. The Duke 446 Regional Biocontianment Laboratory was partially constructed with funding from the NIH/NIAID (UC6-447 AI058607; Gregory Sempowski). The content is solely the responsibility of the authors and does not

448 necessarily represent the official views of the NIH.

449

450 <u>Tables</u>

451

Table 1. Study population characteristics at baseline. The age, race, and self-reported symptoms of 19
 women positive for *N. gonorrhoeae* infection by clinical test who presented at a local STI clinic are
 provided.

455

Baseline characteristics	Symptomatic n = 10	Asymptomatic n = 9	P-value			
Age, mean (range)	21.1 (15-37)	26.6 (16-40)	0.09			
	Black (10)	Black (7)				
Race (n)	Latina (0)	Latina (1)	n/a			
	White (0)	White (1)				
	Vaginal Discharge (90.0)					
Symptoms (%)	Genital irritation (10.0)	None (100.0)	n/a			
	Dysuria (20.0)					

456

457

458 Table 2. Results of clinical Aptima (NAAT) test results and microbial DNA quantitative real-time

459 PCR (qPCR) array. Each column across the categories reflects one individual participant.

460

	<i>N. gonorrhoeae</i> only								N. gonorrhoeae and STI co-infections										
Clinical test	Asymptomatic			Symptomatic				Asymptomatic				Symptomatic							
Aptima GC	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Aptima CT	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-	+	-	+	-
qPCR																			
N. gonorrhoeae	+	+	+	+	+	+	-	+	+	+	+	n/a	n/a	-	+	+	-	+	+
C. trachomatis	-	-	-	-	-	-	-	-	-	-	+	n/a	n/a	-	-	+	-	+	-
M. genitalium	-	-	-	-	-	-	-	-	-	-	-	n/a	n/a	-	-	-	-	-	-
T. vaginalis	-	-	-	-	-	-	-	-	-	+	-	n/a	n/a	+	+	+	+	-	+

461

462 + detected; - not detected; n/a insufficient sample for qPCR; GC, N. gonorrhoeae; CT, C. trachomatis.

463

464 **Figure captions**

465

466 Figure 1. Reads assigned to the *Neisseria* genus comprise a small proportion of the cervicovaginal 467 microbial community. We characterized the genital microbial communities of 19 females with 468 clinically-confirmed gonorrhea using 16S amplicon deep sequencing and microbiome analysis with 469 QIIME. After demultiplexing and eliminating low-quality reads, 100,216 reads were retained for 470 downstream analyses (mean number of reads per sample = 5,274; range = 2,470–9,528 reads). Neisseria-471 assigned 16S ribosomal DNA reads made up only 0.24% of all reads in the dataset and are plotted for 472 each individual's microbial community. No significant differences in relative abundance of 16S reads 473 from *Neisseria spp* between any group was observed using one way ANOVA with Tukey's correction for 474 multiple comparisons. 475 476 Figure 2. Alpha diversity analyses with respect to clinical presentation and other STI co-infection. 477 Alpha diversity was measured by three different metrics (Chao1; and observed species; phylogenetic 478 diversity, PD) at a depth of 2,270 reads and visualized as rarefaction plots. The overall alpha diversity 479 including observed taxa, Chao1 and phylogenetic diversity are plotted for individuals with symptomatic 480 and asymptomatic N. gonorrhoeae infection (A) and for individuals with and without other STI (B). The 481 number of dominant taxa comprising the majority of the microbial community (i.e., 90% of all detected 482 taxa) is plotted for individuals with asymptomatic and symptomatic N. gonorrhoeae infection with and 483 without STI co-infection (C). Statistical significant differences between patient groups were explored 484 with one way ANOVA with Tukey's correction for multiple comparisons. 485 486 487 Figure 3. Beta diversity analyses with respect to clinical presentation and other STI co-infection. 488 Beta diversity estimates were calculated within QIIME using weighted (A) and unweighted Unifrac (B) 489 distances between samples. Results were summarized and visualized through principal coordinate 490 analysis (PCoA) in QIIME. ANOSIM tests were used to assess the strength of the clustering patterns and 491 statistical significance. Differences between symptomatic and asymptomatic patients, but not between 492 patients with and without C. trachomatis and/or T. vaginalis co-infection, were found, with clear 493 separation on PCoA plots by two different methods: weighted Unifrac ANOSIM R = 0.20, p-value = 494 0.032, Figure 3A) and unweighted Unifrac ANOSIM R = 0.24 p-value = 0.011).

495

Figure 4. Community composition of symptomatic and asymptomatic individuals with and without *C. trachomatis* and/or *T. vaginalis* co-infection.

498	The mean relative abundance of the top 5 most prevalent bacterial genera identified within each patient
499	group of interest are plotted as pie charts with each pie representing a group of interest (A). The relative
500	abundances of the top ten taxa (genera or family-level taxa, as applicable) identified across all 16S rRNA
501	sequencing reads in the dataset are shown for each of the 19 participants included in the study. These top
502	10 taxa comprised ≥99% of all reads in the entire dataset. We used BLAST and MUSCLE alignments to
503	determine the likely species of communities dominated by Lactobacillus, Lachnospiraceae and
504	Mycoplasma and found them to be L. iners, Bacterial Vaginosis-Associated Bacterium-1
505	(BVAB1)/"Candidatus Lachnocurva vaginae" and M. hominis, respectively. The microbial community
506	type (CT) designated for each participant, using standard definitions in the field, is provided. (B).
507	
508	
509	Figure 5. Lactobacillus spp. detection with respect to clinical presentation and other STI co-
510	infection.
511	The fraction of reads assigned to Lactobacillus among all sequence reads comprising an individual's
512	microbial community is shown (A). Participants have been grouped by symptom and co-infection status.
513	Statistical significant differences between patient groups were explored with one way ANOVA with
514	Tukey's correction for multiple comparisons. The presence of specific Lactobacillus spp. was also
515	assessed by presence/absence commercially-available real-time PCR assay (B). Participants have been
516	grouped by symptom and co-infection status. The fraction of individuals within each group positive for
517	each of the seven Lactobacillus species in our panel (L. acidophilus, L. crispatus, L. gasseri, L. iners, , L.
518	jensenii, L. salivarius, L. vaginalis) are shown as a heatmap, with values ranging from "0" (i.e. none of
519	the women in the group positive for that species) to "1.0" (i.e. all women in the group positive for that
520	species).
521 522	
523	Figure 6. Prevalence of common bacterial vaginosis-associated bacteria detected with
524	commercially-available microbial DNA real-time PCR assay. The presence of the indicated BV-
525	associated bacterial species was assessed by presence/absence commercially-available real-time PCR
526	assay. Participants have been grouped by symptom and co-infection status. The fraction of individuals
527	within each group positive for each of the seven BV-associated bacteria in the panel are shown as a
528	heatmap, with values ranging from "0" (i.e. none of the women in the group positive for that species) to

529 "1.0" (i.e. all women in the group positive for that species).

530

Figure 7. Abundance of Lactobacillus crispatus and N. gonorrhoeae during controlled gonorrhea

mouse infections. Groups of 4-5 mice were pre-colonized with L. crispatus and then inoculated with

either N. gonorrhoeae strain 1291 (wild-type, wt) or its isogenic strain lacking MsbB (1291-\DeltamsbB).

- Daily vaginal swabs were collected for 10 days and quantitative bacterial cultures for both species were
- performed. Results represent combined bacterial recovery findings from three independent experiments
- (n=3). (A) The average L. crispatus colony forming units (\log_{10} CFU) recovered from daily mouse
- vaginal swabs are shown. The abundance of L. crispatus was not found to be affected by N. gonorrhoeae
- infection. (B) The time to clearance of N. gonorrhoeae strain 1291 in infected mice pre-colonized with
- and without L. crispatus was assessed with Kaplan-Meier curves. (C)The time to clearance of N.
- gonorrhoeae strain 1291- $\Delta msbB$ in infected mice pre-colonized with and without L. crispatus was
- assessed with Kaplan-Meier curves.

Bibliography

- 1. Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ 2019; 97:548-62P.
- - 2. Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic gonorrhea in men.
 - Diagnosis, natural course, prevalence and significance. N Engl J Med 1974; 290:117-23.
 - 3. Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal
 - adnexal findings among women recently exposed to gonorrhea. JAMA 1983; 250:3205-9.

- 4. Sandstrom EG, Knapp JS, Reller LB, Thompson SE, Hook EW, 3rd, Holmes KK. Serogrouping of
- 565 Neisseria gonorrhoeae: correlation of serogroup with disseminated gonococcal infection. Sex

566 Transm Dis **1984**; 11:77-80.

- 567 5. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and
- 568 gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco,
- 569 California, 2003. Clin Infect Dis **2005**; 41:67-74.
- 570 6. Lovett A, Duncan JA. Human Immune Responses and the Natural History of Neisseria 571 gonorrhoeae Infection. Front Immunol **2018**; 9:3187.
- 572 7. Potterat JJ, Dukes RL, Rothenberg RB. Disease transmission by heterosexual men with 573 gonorrhea: an empiric estimate. Sex Transm Dis **1987**; 14:107-10.
- 574 8. Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med 575 **1996**; 72:422-6.
- 576 9. Martin-Sanchez M, Ong JJ, Fairley CK, et al. Clinical presentation of asymptomatic and
- 577 symptomatic heterosexual men who tested positive for urethral gonorrhoea at a sexual health 578 clinic in Melbourne, Australia. BMC Infect Dis **2020**; 20:486.
- 579 10. Ong JJ, Fethers K, Howden BP, et al. Asymptomatic and symptomatic urethral gonorrhoea in
 580 men who have sex with men attending a sexual health service. Clin Microbiol Infect **2017**; 23:555581 9.
- 582 11. Hazel A, Ponnaluri-Wears S, Davis GS, Low BS, Foxman B. High prevalence of Neisseria 583 gonorrhoeae in a remote, undertreated population of Namibian pastoralists. Epidemiol Infect 584 **2014**; 142:2422-32.
- 585 12. Reekie J, Donovan B, Guy R, et al. Risk of Ectopic Pregnancy and Tubal Infertility Following 586 Gonorrhea and Chlamydia Infections. Clin Infect Dis **2019**; 69:1621-3.
- 13. Reekie J, Donovan B, Guy R, et al. Risk of Pelvic Inflammatory Disease in Relation to Chlamydia
 and Gonorrhea Testing, Repeat Testing, and Positivity: A Population-Based Cohort Study. Clin
 Infect Dis **2018**; 66:437-43.
- 590 14. Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical pelvic inflammatory 591 disease and infertility. Obstet Gynecol **2012**; 120:37-43.
- 592 15. Hazel A, Marino S, Simon C. An anthropologically based model of the impact of asymptomatic
- 593 cases on the spread of Neisseria gonorrhoeae. J R Soc Interface **2015**; 12.
- 16. Aroutcheva A, Gariti D, Simon M, et al. Defense factors of vaginal lactobacilli. Am J ObstetGynecol 2001; 185:375-9.
- 17. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition:
 a meta-analysis of published studies. AIDS **2008**; 22:1493-501.
- 598 18. Coleman JS, Hitti J, Bukusi EA, et al. Infectious correlates of HIV-1 shedding in the female 599 upper and lower genital tracts. AIDS **2007**; 21:755-9.
- 600 19. McClelland RS, Lingappa JR, Srinivasan S, et al. Evaluation of the association between the
- 601 concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women
- 602 from five cohorts: a nested case-control study. Lancet Infect Dis **2018**; 18:554-64.
- 603 20. Sha BE, Zariffard MR, Wang QJ, et al. Female genital-tract HIV load correlates inversely with
- Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis2005; 191:25-32.
- 606 21. Anahtar MN, Byrne EH, Doherty KE, et al. Cervicovaginal bacteria are a major modulator of
- 607 host inflammatory responses in the female genital tract. Immunity **2015**; 42:965-76.

- 608 22. Masson L, Mlisana K, Little F, et al. Defining genital tract cytokine signatures of sexually
- 609 transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-610 sectional study. Sex Transm Infect 2014; 90:580-7.
- 611 23. Masson L, Passmore JA, Liebenberg LJ, et al. Genital inflammation and the risk of HIV 612 acquisition in women. Clin Infect Dis 2015; 61:260-9.

613 24. Borgdorff H, Tsivtsivadze E, Verhelst R, et al. Lactobacillus-dominated cervicovaginal 614 microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African

- 615 women. ISME J 2014; 8:1781-93.
- 616 25. Tamarelle J, Thiebaut ACM, de Barbeyrac B, Bebear C, Ravel J, Delarocque-Astagneau E. The
- 617 vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, 618 Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-
- 619 analysis. Clin Microbiol Infect 2019; 25:35-47.
- 620 26. van der Veer C, Bruisten SM, van der Helm JJ, de Vries HJ, van Houdt R. The Cervicovaginal
- 621 Microbiota in Women Notified for Chlamydia trachomatis Infection: A Case-Control Study at the
- 622 Sexually Transmitted Infection Outpatient Clinic in Amsterdam, The Netherlands. Clin Infect Dis 623 **2017**; 64:24-31.
- 624 27. Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-Deficient Cervicovaginal Bacterial
- 625 Communities Are Associated with Increased HIV Acquisition in Young South African Women. 626 Immunity 2017; 46:29-37.
- 627 28. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong 628 predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003;
- 629 36:663-8.
- 630 29. Gallo MF, Macaluso M, Warner L, et al. Bacterial vaginosis, gonorrhea, and chlamydial
- 631 infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of
- 632 possible causal links. Ann Epidemiol 2012; 22:213-20.
- 633 30. Bautista CT, Wurapa EK, Sateren WB, Morris SM, Hollingsworth BP, Sanchez JL. Association of
- 634 Bacterial Vaginosis With Chlamydia and Gonorrhea Among Women in the U.S. Army. Am J Prev
- 635 Med 2017; 52:632-9.
- 636 31. Elovitz MA, Gajer P, Riis V, et al. Cervicovaginal microbiota and local immune response 637 modulate the risk of spontaneous preterm delivery. Nat Commun **2019**; 10:1305.
- 638 32. Fettweis JM, Serrano MG, Brooks JP, et al. The vaginal microbiome and preterm birth. Nat 639 Med 2019; 25:1012-21.
- 640 33. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic 641 perspective. J Clin Invest 2011; 121:4610-7.
- 642 34. McKinnon LR, Achilles SL, Bradshaw CS, et al. The Evolving Facets of Bacterial Vaginosis: 643 Implications for HIV Transmission. AIDS Res Hum Retroviruses 2019; 35:219-28.
- 644 35. Tuddenham S, Ravel J, Marrazzo JM. Protection and Risk: Male and Female Genital Microbiota 645
- and Sexually Transmitted Infections. J Infect Dis 2021; 223:S222-S35.
- 646 36. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl 647 Acad Sci U S A 2011; 108 Suppl 1:4680-7.
- 648 37. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis.
- 649 Diagnostic criteria and microbial and epidemiologic associations. Am J Med **1983**; 74:14-22.
- 650 38. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs of
- 651 Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis 2019; 46:304-11.

- 652 39. Srinivasan S, Hoffman NG, Morgan MT, et al. Bacterial communities in women with bacterial
- vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinicalcriteria. PLoS One **2012**; 7:e37818.
- 40. Joag V, Obila O, Gajer P, et al. Impact of Standard Bacterial Vaginosis Treatment on the Genital
- 656 Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility. Clin
- 657 Infect Dis **2019**; 68:1675-83.
- 41. Lennard K, Dabee S, Barnabas SL, et al. Microbial Composition Predicts Genital Tract
 Inflammation and Persistent Bacterial Vaginosis in South African Adolescent Females. Infect
 Immun 2018; 86.
- 42. Cohen CR, Moscicki AB, Scott ME, et al. Increased levels of immune activation in the genital
 tract of healthy young women from sub-Saharan Africa. AIDS **2010**; 24:2069-74.
- 663 43. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput 664 community sequencing data. Nat Methods **2010**; 7:335-6.
- 66544. FastQC: A Quality Control Tool for High Throughput Sequence Data [Online]. Available online666at:http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (2015), "FastQC,"
- 667 <u>https://qubeshub.org/resources/fastqc</u>.
- 45. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics **2010**;26:2460-1.
- 670 46. Rognes T, Flouri T, Nichols B, Quince C, Mahe F. VSEARCH: a versatile open source tool for 671 metagenomics. PeerJ **2016**; 4:e2584.
- 47. Haas BJ, Gevers D, Earl AM, et al. Chimeric 16S rRNA sequence formation and detection in
 Sanger and 454-pyrosequenced PCR amplicons. Genome Res **2011**; 21:494-504.
- 48. DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol **2006**; 72:5069-72.
- 676 49. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, Knight R. PyNAST: a flexible 677 tool for aligning sequences to a template alignment. Bioinformatics **2010**; 26:266-7.
- 678 50. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large 679 alignments. PLoS One **2010**; 5:e9490.
- 51. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J MolBiol **1990**; 215:403-10.
- 52. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial
 communities. Appl Environ Microbiol **2005**; 71:8228-35.
- 53. Jerse AE, Wu H, Packiam M, Vonck RA, Begum AA, Garvin LE. Estradiol-Treated Female Mice
 as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Front Microbiol **2011**;
 2:107.
- 687 54. Zhou X, Gao X, Broglie PM, et al. Hexa-acylated lipid A is required for host inflammatory 688 response to Neisseria gonorrhoeae in experimental gonorrhea. Infect Immun **2014**; 82:184-92.
- 55. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput.
- 690 Nucleic Acids Res **2004**; 32:1792-7.
- 691 56. Muench DF, Kuch DJ, Wu H, et al. Hydrogen peroxide-producing lactobacilli inhibit gonococci
- 692 in vitro but not during experimental genital tract infection. J Infect Dis **2009**; 199:1369-78.
- 693 57. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of
- 694 human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis
- 695 **1999**; 180:1863-8.

- 58. Schwebke JR, Lee JY, Lensing S, et al. Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases. Clin Infect Dis **2016**; 62:531-6.
- 59. Witkin SS, Linhares IM. Why do lactobacilli dominate the human vaginal microbiota? BJOG2017; 124:606-11.
- 60. van de Wijgert J, Verwijs MC. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial
- 701 Vaginosis. N Engl J Med **2020**; 383:790-1.
- 702 61. Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African
- American women versus women of European ancestry. Microbiology (Reading) 2014; 160:227282.
- 705 62. Zhou X, Brown CJ, Abdo Z, et al. Differences in the composition of vaginal microbial
 706 communities found in healthy Caucasian and black women. ISME J 2007; 1:121-33.
- 63. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and
 Nutrition Examination Survey data. Obstet Gynecol 2007; 109:114-20.
- 709 64. Vielfort K, Sjolinder H, Roos S, Jonsson H, Aro H. Adherence of clinically isolated lactobacilli to
- human cervical cells in competition with Neisseria gonorrhoeae. Microbes Infect **2008**; 10:1325-34.
- 65. Graver MA, Wade JJ. The role of acidification in the inhibition of Neisseria gonorrhoeae by
 vaginal lactobacilli during anaerobic growth. Ann Clin Microbiol Antimicrob 2011; 10:8.
- 66. Tachedjian G, Aldunate M, Bradshaw CS, Cone RA. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol **2017**; 168:782-92.
- 716 67. Spurbeck RR, Arvidson CG. Lactobacillus jensenii surface-associated proteins inhibit Neisseria
- 717 gonorrhoeae adherence to epithelial cells. Infect Immun **2010**; 78:3103-11.
- 68. Edwards VL, Smith SB, McComb EJ, et al. The Cervicovaginal Microbiota-Host Interaction
 Modulates Chlamydia trachomatis Infection. mBio **2019**; 10.
- 69. Nunn KL, Wang YY, Harit D, et al. Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus
 Is Associated with Lactobacillus crispatus-Dominant Microbiota. mBio **2015**; 6:e01084-15.
- 722 70. Holm JB, France MT, Ma B, et al. Comparative Metagenome-Assembled Genome Analysis of
- 723 "Candidatus Lachnocurva vaginae", Formerly Known as Bacterial Vaginosis-Associated 724 Bacterium-1 (BVAB1). Front Cell Infect Microbiol **2020**; 10:117.
- 725 71. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with 726 bacterial vaginosis. N Engl J Med **2005**; 353:1899-911.
- 727 72. Onderdonk AB, Delaney ML, Fichorova RN. The Human Microbiome during Bacterial728 Vaginosis. Clin Microbiol Rev **2016**; 29:223-38.
- 729 73. Rumyantseva T, Khayrullina G, Guschin A, Donders G. Prevalence of Ureaplasma spp. and
- 730 Mycoplasma hominis in healthy women and patients with flora alterations. Diagn Microbiol 731 Infect Dis **2019**; 93:227-31.
- 732 74. Martin DH, Zozaya M, Lillis RA, Myers L, Nsuami MJ, Ferris MJ. Unique vaginal microbiota that
- includes an unknown Mycoplasma-like organism is associated with Trichomonas vaginalisinfection. J Infect Dis **2013**; 207:1922-31.
- 735 75. Kyongo JK, Crucitti T, Menten J, et al. Cross-Sectional Analysis of Selected Genital Tract
- 736 Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with
- 737 Relevance to HIV Risk and Prevention. Clin Vaccine Immunol **2015**; 22:526-38.
- 738





B. Alpha diversity by C. trachomatis or T. vaginalis co-infection







A. Weighted Unifrac



B. Unweighted Unifrac





B.





Β.

A.



N. gonorrhoeae, with C. trachomatis and/or T. vaginalis coinfection



	N. gonorrh	oeae-only N.	gonorrhoeae, with C. trachomatis and/or T. vaginalis coinfection						
	Asymptomatic	Symptomatic	Asymptomatic	Symptomatic	י 	0			
Atopobium vaginae	0.50	0.80	1.00	1.00		0			
Fusobacterium nucleatum	0.00	0.00	0.00	0.40					
Gardnerella vaginalis	1.00	1.00	1.00	1.00					
Mobiluncus curtisii	0.25	0.20	0.67	0.20		0.2			
Mobiluncus mulieris	0.25	0.20	0.00	0.20					
Mycoplasma hominis	0.25	0.80	1.00	0.80					
Peptostreptococcus anaerobius	0.00	0.00	1.00	0.60		• •			
Porphyromonas asaccharolytica	0.00	0.20	0.33	0.20		0.4			
Prevotella bivia	0.50	0.40	1.00	0.80					
Prevotella buccalis	0.25	0.80	0.67	1.00					
Prevotella disiens	0.50	0.00	0.67	0.40		06			
Prevotella intermedia	0.00	0.00	0.00	0.20		0.0			
Prevotella melaninogenica	0.00	0.20	0.33	0.40					
Sneathia sanguinegens	0.50	0.80	1.00	1.00					
Streptococcus anginosus	0.50	0.20	0.67	0.40		0.8			
Streptococcus mitis	0.00	0.20	0.00	0.00					
Streptococcus thermophilus, S. salivarius	0.00	0.20	0.33	0.00					
Ureaplasma parvum	0.75	0.40	0.33	0.20					
Ureaplasma urealyticum	0.00	1.00	0.00	0.00		1.0			

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display It is made available under a CC-BY-NC-ND 4.0 International license .

Α.

Β.

C.



- Ng (strain 1291- $\Delta msbB$) - Lc + Ng (strain 1291- $\Delta msbB$)